{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:14:50Z","timestamp":1792790090822,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Boehringer Ingelheim"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02864-9","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T09:11:37Z","timestamp":1758618697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment and associated outcomes of type 2 diabetes mellitus patients with a cardiovascular comorbidity and comparison with guideline recommendations: a German claims data analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Jens","family":"Aberle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Duerschmied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Grond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lehrke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven-Oliver","family":"Tr\u00f6bs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schultze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Kossack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena Margareta","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Gabler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"2864_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110708","volume":"131","author":"S Padhi","year":"2020","unstructured":"Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: a review on recent drug based therapeutics. Biomed Pharmacother. 2020;131: 110708. https:\/\/doi.org\/10.1016\/j.biopha.2020.110708.","journal-title":"Biomed Pharmacother"},{"key":"2864_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ecl.2021.05.013","volume":"50","author":"MG Tinajero","year":"2021","unstructured":"Tinajero MG, Malik VS. An update on the epidemiology of type 2 diabetes: a global perspective. Endocrinol Metab Clin North Am. 2021;50:337\u201355. https:\/\/doi.org\/10.1016\/j.ecl.2021.05.013.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2864_CR3","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2022.0405","author":"T T\u00f6nnies","year":"2023","unstructured":"T\u00f6nnies T, Hoyer A, Brinks R, Kuss O, Hering R, Schulz M. Spatio-temporal trends in the incidence of type 2 diabetes in Germany-analysis of the claims data of 63 million persons with statutory health insurance from 2014 to 2019. Deutsches Arzteblatt Int. 2023. https:\/\/doi.org\/10.3238\/arztebl.m2022.0405.","journal-title":"Deutsches Arzteblatt Int"},{"key":"2864_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3238\/arztebl.2016.0177","volume":"113","author":"T Tamayo","year":"2016","unstructured":"Tamayo T, Brinks R, Hoyer A, Ku\u00df OS, Rathmann W. The prevalence and incidence of diabetes in Germany. Dtsch Arztebl Int. 2016;113:177\u201382. https:\/\/doi.org\/10.3238\/arztebl.2016.0177.","journal-title":"Dtsch Arztebl Int"},{"key":"2864_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264739","volume":"17","author":"D Voeltz","year":"2022","unstructured":"Voeltz D, T\u00f6nnies T, Brinks R, Hoyer A. Future prevalence of type 2 diabetes-a comparative analysis of chronic disease projection methods. PLoS ONE. 2022;17: e0264739. https:\/\/doi.org\/10.1371\/journal.pone.0264739.","journal-title":"PLoS ONE"},{"key":"2864_CR6","unstructured":"International Diabetes Federation. IDF diabetes Atlas. 2021. https:\/\/www.diabetesatlas.org."},{"key":"2864_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01516-6","volume":"21","author":"C-X Ma","year":"2022","unstructured":"Ma C-X, Ma X-N, Guan C-H, Li Y-D, Mauricio D, Fu S-B. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol. 2022;21: 74. https:\/\/doi.org\/10.1186\/s12933-022-01516-6.","journal-title":"Cardiovasc Diabetol"},{"key":"2864_CR8","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.amjcard.2017.05.014","volume":"120","author":"M Lehrke","year":"2017","unstructured":"Lehrke M, Marx N. Diabetes mellitus and heart failure. Am J Cardiol. 2017;120:S37\u201347. https:\/\/doi.org\/10.1016\/j.amjcard.2017.05.014.","journal-title":"Am J Cardiol"},{"key":"2864_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018;17:83. https:\/\/doi.org\/10.1186\/s12933-018-0728-6.","journal-title":"Cardiovasc Diabetol"},{"key":"2864_CR10","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"L Ryd\u00e9n","year":"2013","unstructured":"Ryd\u00e9n L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035\u201387. https:\/\/doi.org\/10.1093\/eurheartj\/eht108.","journal-title":"Eur Heart J"},{"key":"2864_CR11","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1055\/a-1018-9106","volume":"127","author":"R Landgraf","year":"2019","unstructured":"Landgraf R, Aberle J, Birkenfeld AL, Gallwitz B, Kellerer M, Klein H, et al. Therapy of type 2 diabetes. Exp Clin Endocrinol Diabetes. 2019;127:S73\u201392. https:\/\/doi.org\/10.1055\/a-1018-9106.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2864_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S2213-8587(21)00113-3","volume":"9","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol. 2021;9:525\u201344. https:\/\/doi.org\/10.1016\/S2213-8587(21)00113-3.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2864_CR13","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s13300-021-01024-y","volume":"12","author":"M Gabler","year":"2021","unstructured":"Gabler M, Picker N, Geier S, Ley L, Aberle J, Lehrke M, et al. Guideline adherence and associated outcomes in the treatment of type 2 diabetes mellitus patients with an incident cardiovascular comorbidity: an analysis based on a large German claims dataset. Diabetes Ther. 2021;12:1209\u201326. https:\/\/doi.org\/10.1007\/s13300-021-01024-y.","journal-title":"Diabetes Ther"},{"key":"2864_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12913-014-0669-z","volume":"15","author":"SF Oude Wesselink","year":"2015","unstructured":"Oude Wesselink SF, Lingsma HF, Robben PBM, Mackenbach JP. Guideline adherence and health outcomes in diabetes mellitus type 2 patients: a cross-sectional study. BMC Health Serv Res. 2015;15:22. https:\/\/doi.org\/10.1186\/s12913-014-0669-z.","journal-title":"BMC Health Serv Res"},{"key":"2864_CR15","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1007\/s13300-020-00935-6","volume":"11","author":"N Papanas","year":"2020","unstructured":"Papanas N, Elisaf M, Kotsa K, Melidonis A, Bousboulas S, Bargiota A, et al. Adherence to the national guidelines for follow-up protocol in subjects with type 2 diabetes mellitus in Greece: the GLANCE study. Diabetes Ther. 2020;11:2887\u2013908. https:\/\/doi.org\/10.1007\/s13300-020-00935-6.","journal-title":"Diabetes Ther"},{"key":"2864_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2018-000639","volume":"7","author":"SA Karlsson","year":"2019","unstructured":"Karlsson SA, Eliasson B, Franz\u00e9n S, Miftaraj M, Svensson A-M, Andersson Sundell K. Risk of cardiovascular event and mortality in relation to refill and guideline adherence to lipid-lowering medications among patients with type 2 diabetes mellitus in Sweden. BMJ Open Diabetes Res Care. 2019;7: e000639. https:\/\/doi.org\/10.1136\/bmjdrc-2018-000639.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2864_CR17","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3655","volume":"100","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder S, Ketz M, Kossack N, Akumo D, Pignot M, Gabriel S, Chavda R. Epidemiology of prurigo nodularis compared with psoriasis in Germany: a claims database analysis. Acta Derm Venereol. 2020;100: adv00309. https:\/\/doi.org\/10.2340\/00015555-3655.","journal-title":"Acta Derm Venereol"},{"key":"2864_CR18","first-page":"e45","volume":"25","author":"FS Wicke","year":"2019","unstructured":"Wicke FS, Glushan A, Schubert I, K\u00f6ster I, L\u00fcbeck R, Hammer M, et al. Performance of the adapted Diabetes Complications Severity Index translated to ICD-10. Am J Manag Care. 2019;25:e45\u20139.","journal-title":"Am J Manag Care"},{"key":"2864_CR19","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676\u201382. https:\/\/doi.org\/10.1093\/aje\/kwq433.","journal-title":"Am J Epidemiol"},{"key":"2864_CR20","unstructured":"AWMF-Register-Nr.: nvl-001, Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2Diabetes\u2013 Langfassung, 1. Auflage. Version 4. 2014. https:\/\/www.leitlinien.de\/themen\/diabetes\/archiv\/pdf\/therapie-des-typ-2-diabetes\/dm-therapie-1aufl-vers4-lang.pdf. Accessed 4 Apr 2023."},{"key":"2864_CR21","unstructured":"AWMF-Register Nr. 030\u2013133: Hamann GF, Sander D, R\u00f6ther J, Grau A et al. Deutsche Schlaganfall-Gesellschaft und Deutsche Gesellschaft f\u00fcr Neurologie. S3-Leitlinie\u2013 Teil 1 - Sekund\u00e4rprophylaxe isch\u00e4mischer Schlaganfall und transitorische isch\u00e4mische Attacke, Version 1. 2015. www.awmf.org. Accessed 4 Apr 2023."},{"key":"2864_CR22","unstructured":"ESC Pocket Guidelines. Therapie des akuten Herzinfarktes bei Patienten mit ST-Streckenhebung (STEMI), Version 2017: Kurzfassung der \u201cESC Guidelines for the Management of Acute Myocardial Infarction in Patients presenting with ST-segment Elevation\u201c."},{"key":"2864_CR23","unstructured":"AWMF-Register-Nr.: nvl-006, Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz\u2013 Langfassung, 2. Auflage. Version 3. 2018. from: https:\/\/www.leitlinien.de\/themen\/herzinsuffizienz\/archiv\/pdf\/herzinsuffizienz-2aufl-vers3-lang.pdf. Accessed 4 Apr 2023."},{"key":"2864_CR24","unstructured":"AWMF-Register-Nr.: nvl-004, Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK\u2013 Langfassung, 4. Auflage. Version 1. 2016. https:\/\/www.leitlinien.de\/themen\/khk\/archiv\/pdf\/khk-4aufl-vers1-lang-2.pdf."},{"key":"2864_CR25","unstructured":"ESC Pocket Guidelines. Akutes Koronarsyndrom ohne ST-Hebung (NSTE-ACS), Version 2015: Kurzfassung der \"ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-segment Elevation\u201c. https:\/\/leitlinien.dgk.org\/files\/18_2015_pocket_leitlinien_nste_acs.pdf. Accessed 4 Apr 2023."},{"key":"2864_CR26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40266-013-0074-z","volume":"30","author":"ELP Sattler","year":"2013","unstructured":"Sattler ELP, Lee JS, Perri M. Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature. Drugs Aging. 2013;30:383\u201399. https:\/\/doi.org\/10.1007\/s40266-013-0074-z.","journal-title":"Drugs Aging"},{"key":"2864_CR27","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","volume":"61","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, a consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetologia. 2018;61:2461\u201398. https:\/\/doi.org\/10.1007\/s00125-018-4729-5.","journal-title":"Diabetologia"},{"key":"2864_CR28","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5.","journal-title":"Lancet"},{"key":"2864_CR29","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.2337\/dc05-2465","volume":"29","author":"J Shepherd","year":"2006","unstructured":"Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart J-C, Haffner S, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the treating to new targets (TNT) study. Diabetes Care. 2006;29:1220\u20136. https:\/\/doi.org\/10.2337\/dc05-2465.","journal-title":"Diabetes Care"},{"key":"2864_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/eurheartj\/ehr400","volume":"33","author":"FA McAlister","year":"2012","unstructured":"McAlister FA. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials. Eur Heart J. 2012;33:505\u201314. https:\/\/doi.org\/10.1093\/eurheartj\/ehr400.","journal-title":"Eur Heart J"},{"key":"2864_CR31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145\u201353. https:\/\/doi.org\/10.1056\/NEJM200001203420301.","journal-title":"N Engl J Med"},{"key":"2864_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X.","journal-title":"Lancet"},{"key":"2864_CR33","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776\u201385. https:\/\/doi.org\/10.1016\/S2213-8587(19)30249-9.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2864_CR34","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1177\/2047487314529353","volume":"22","author":"V Gyberg","year":"2015","unstructured":"Gyberg V, Kotseva K, Dallongeville J, de Backer G, Mellbin L, Ryd\u00e9n L, et al. Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study. Eur J Prev Cardiol. 2015;22:753\u201361. https:\/\/doi.org\/10.1177\/2047487314529353.","journal-title":"Eur J Prev Cardiol"},{"key":"2864_CR35","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12933-016-0391-8","volume":"15","author":"B Bohn","year":"2016","unstructured":"Bohn B, Sch\u00f6fl C, Zimmer V, Hummel M, Heise N, Siegel E, et al. Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German\/Austrian DPV-multicenter analysis. Cardiovasc Diabetol. 2016;15:72. https:\/\/doi.org\/10.1186\/s12933-016-0391-8.","journal-title":"Cardiovasc Diabetol"},{"key":"2864_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4573","volume":"372","author":"SC Palmer","year":"2021","unstructured":"Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372: m4573. https:\/\/doi.org\/10.1136\/bmj.m4573.","journal-title":"BMJ"},{"key":"2864_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-01026-2","volume":"22","author":"SV Arnold","year":"2022","unstructured":"Arnold SV, Tang F, Cooper A, Chen H, Gomes MB, Rathmann W, et al. Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER. BMC Endocr Disord. 2022;22: 111. https:\/\/doi.org\/10.1186\/s12902-022-01026-2.","journal-title":"BMC Endocr Disord"},{"key":"2864_CR38","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10198-022-01486-2","volume":"24","author":"M H\u00f6glinger","year":"2023","unstructured":"H\u00f6glinger M, Wirth B, Carlander M, Caviglia C, Frei C, Rhomberg B, et al. Impact of a diabetes disease management program on guideline-adherent care, hospitalization risk and health care costs: a propensity score matching study using real-world data. Eur J Health Econ. 2023;24:469\u201378. https:\/\/doi.org\/10.1007\/s10198-022-01486-2.","journal-title":"Eur J Health Econ"},{"key":"2864_CR39","unstructured":"Bundesversicherungsamt. Auswertungen zum RSA-Jahresvergleich. 2013. https:\/\/www.bundesamtsozialesicherung.de\/fileadmin\/redaktion\/Risikostrukturausgleich\/Info-Dateien%20und%20Auswertungen\/Auswertung_JA_2013.pdf. Accessed 12 Dec 2024."}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02864-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02864-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02864-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:17:57Z","timestamp":1758719877000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02864-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2864"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02864-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complied with relevant European and German data protection regulations. All patient-level data in the database were anonymized. No direct contact with patients or primary collection of individual human patient data occurred and, thus, no informed consent was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"DD has received speaker\u2019s honoraria from Bayer Healthcare, AOP Health, AstraZeneca, Pfizer, Daiichi Sankyo, Boston Scientific and consulting fees from Daiichi Sankyo, Boston Scientific, CSL Behring, and Janssen. ML received grants and personal fees from Boehringer Ingelheim, MSD, Novo Nordisk and personal fees from Amgen, Sanofi, Astra Zeneca, Bayer, Lilly, Daiichi Sankyo, Novartis, Amarin, Abiomed, BMS, and Pfizer. MGr received speaker\u2019s honoraria and honoraria for advisory boards from Boehringer Ingelheim, Bayer vital, Pfizer, AstraZeneca, Novo Nordisc, iRhythm, Alexion and streamed-up. SM received grants from Fractly and Almased, speaker\u2019s honoraria from Astra Zeneca, Lilly, Boehringer Ingelheim, StreamedUp, MedUpdate, Bayer, and Marpinion, and consultant fees from AXA Versicherung, Generali Versicherung, Fractly, Almased, Boehringer Ingelheim, Bionorica, and gbo Ger\u00e4tebau. MS is an employee of Berlin Center for Epidemiology and Health Research (ZEG) at the time of the study, which was contracted by Boehringer Ingelheim to conduct this study. NK and LR are employees of Scientific Institute for Health Economics and Health System Research (WIG2) at the time of the study, which was contracted by Boehringer Ingelheim to conduct this study. MGa and SOT are employees of Boehringer Ingelheim.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"364"}}